Humar Atul, Kumar Deepali, Gilbert Christian, Boivin Guy
Department of Medicine, Division of Multi-Organ Transplantation, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.
J Infect Dis. 2003 Aug 15;188(4):581-4. doi: 10.1086/377002. Epub 2003 Jul 29.
Cytomegalovirus (CMV) can be classified into 4 glycoprotein B (gB) genotypes, on the basis of sequence variation in the UL55 gene. We assessed the effect that CMV gB genotype has on virologic and clinical response to therapy, in 50 solid-organ-transplant recipients with CMV disease. CMV loads were determined at regular intervals after the start of therapy. Genotype results were correlated with CMV-load kinetics in response to therapy with ganciclovir. At the onset of treatment, the distribution of CMV gB genotypes was as follows: gB1, 19/50 (38%); gB2, 9/50 (18%); gB3, 12/50 (24%); gB4, 2/50 (4%); and mixed-genotype infection, 8/50 (16%). Between viral genotype groups, time to clearance of CMV, failure to clear CMV, and calculated CMV-load half-life after the start of therapy were not significantly different. The CMV gB genotype did not affect the rate of disease recurrence or occurrence of tissue-invasive disease. It appears that the gB genotype, which causes CMV disease, does not significantly influence CMV-load kinetics or clinical response to therapy.
根据UL55基因的序列变异，巨细胞病毒（CMV）可分为4种糖蛋白B（gB）基因型。我们评估了CMV gB基因型对50例患有CMV疾病的实体器官移植受者的病毒学和治疗临床反应的影响。治疗开始后定期测定CMV载量。将基因型结果与更昔洛韦治疗反应中的CMV载量动力学相关联。治疗开始时，CMV gB基因型的分布如下：gB1，19/50（38%）；gB2，9/50（18%）；gB3，12/50（24%）；gB4，2/50（4%）；混合基因型感染，8/50（16%）。在病毒基因型组之间，治疗开始后CMV清除时间、未清除CMV以及计算出的CMV载量半衰期无显著差异。CMV gB基因型不影响疾病复发率或组织侵袭性疾病的发生。似乎导致CMV疾病的gB基因型不会显著影响CMV载量动力学或治疗临床反应。
